{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T11:56:55Z","timestamp":1792065415887,"version":"4.4.0"},"reference-count":57,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T00:00:00Z","timestamp":1782259200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["advancesradonc.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Advances in Radiation Oncology"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.adro.2026.102128","type":"journal-article","created":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T15:39:03Z","timestamp":1782920343000},"page":"102128","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Neoadjuvant Early Stereotactic Body Radiation Therapy Followed by Chemoimmunotherapy in Borderline Resectable and Locally Advanced Pancreatic Cancer"],"prefix":"10.1016","volume":"11","author":[{"given":"Shuhan","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ShanMiao","family":"Gou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenyu","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianli","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongli","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxue","family":"Gou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heshui","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7323-0331","authenticated-orcid":false,"given":"Jun","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.adro.2026.102128_bib0001","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1016\/S0140-6736(25)00261-2","article-title":"Pancreatic cancer","volume":"405","author":"Stoop","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.adro.2026.102128_bib0002","doi-asserted-by":"crossref","first-page":"10740","DOI":"10.3748\/wjg.v20.i31.10740","article-title":"Borderline resectable pancreatic cancer: Definitions and management","volume":"20","author":"Lopez","year":"2014","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.adro.2026.102128_bib0003","doi-asserted-by":"crossref","first-page":"439","DOI":"10.6004\/jnccn.2021.0017","article-title":"Pancreatic adenocarcinoma, version 2.2021, NCCN clinical practice guidelines in oncology","volume":"19","author":"Tempero","year":"2021","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.adro.2026.102128_bib0004","article-title":"Neoadjuvant therapy for pancreatic ductal adenocarcinoma: Where do we go?","volume":"12","author":"Wang","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.adro.2026.102128_bib0005","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1056\/NEJMoa1809775","article-title":"FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer","volume":"379","author":"Conroy","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.adro.2026.102128_bib0006","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2024.102750","article-title":"Neoadjuvant management of locally advanced pancreatic ductal adenocarcinoma - Heading towards a promising change in treatment paradigm","volume":"127","author":"Mahmood","year":"2024","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.adro.2026.102128_bib0007","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/j.annonc.2023.08.009","article-title":"Pancreatic cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"34","author":"Conroy","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.adro.2026.102128_bib0008","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1097\/SLA.0000000000005430","article-title":"Results of a phase II study on the use of neoadjuvant chemotherapy (FOLFIRINOX or GEM\/nab-PTX) for borderline-resectable pancreatic cancer (NUPAT-01)","volume":"275","author":"Yamaguchi","year":"2022","journal-title":"Ann Surg"},{"key":"10.1016\/j.adro.2026.102128_bib0009","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.ejca.2022.12.014","article-title":"A randomised phase II study of modified FOLFIRINOX versus gemcitabine plus nab-paclitaxel for locally advanced pancreatic cancer (JCOG1407)","volume":"181","author":"Ozaka","year":"2023","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.adro.2026.102128_bib0010","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.17625","article-title":"Pathological complete response in patients with resected pancreatic adenocarcinoma after preoperative chemotherapy","volume":"7","author":"Stoop","year":"2024","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.adro.2026.102128_bib0011","doi-asserted-by":"crossref","first-page":"8297","DOI":"10.1245\/s10434-021-10276-8","article-title":"Added value of radiotherapy following neoadjuvant FOLFIRINOX for resectable and borderline resectable pancreatic cancer: A systematic review and meta-analysis","volume":"28","author":"Janssen","year":"2021","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.adro.2026.102128_bib0012","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1001\/jamaoncol.2022.2319","article-title":"Efficacy of preoperative mFOLFIRINOX vs mFOLFIRINOX plus hypofractionated radiotherapy for borderline resectable adenocarcinoma of the pancreas: The A021501 phase 2 randomized clinical trial","volume":"8","author":"Katz","year":"2022","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.adro.2026.102128_bib0013","doi-asserted-by":"crossref","first-page":"2789","DOI":"10.1200\/JCO.21.02616","article-title":"Immunologic strategies in pancreatic cancer: Making cold tumors hot","volume":"40","author":"Ullman","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.adro.2026.102128_bib0014","article-title":"Randomized phase II trial of neoadjuvant chemotherapy with modified FOLFIRINOX versus modified FOLFIRINOX and PD-1 antibody for borderline resectable and locally advanced pancreatic cancer (the CISPD-4 study)","volume":"40","author":"Chen","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.adro.2026.102128_bib0015","doi-asserted-by":"crossref","first-page":"eadk1827","DOI":"10.1126\/sciadv.adk1827","article-title":"Neoadjuvant radioimmunotherapy in pancreatic cancer enhances effector T cell infiltration and shortens their distances to tumor cells","volume":"10","author":"Wang","year":"2024","journal-title":"Sci Adv"},{"key":"10.1016\/j.adro.2026.102128_bib0016","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s13045-023-01422-8","article-title":"Nab-paclitaxel and gemcitabine plus camrelizumab and radiotherapy versus nab-paclitaxel and gemcitabine alone for locally advanced pancreatic adenocarcinoma: A prospective cohort study","volume":"16","author":"Chen","year":"2023","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.adro.2026.102128_bib0017","doi-asserted-by":"crossref","first-page":"859","DOI":"10.5306\/wjco.v15.i7.859","article-title":"Programmed cell death 1 inhibitor sintilimab plus concurrent chemoradiotherapy for locally advanced pancreatic adenocarcinoma","volume":"15","author":"Zhou","year":"2024","journal-title":"World J Clin Oncol"},{"key":"10.1016\/j.adro.2026.102128_bib0018","article-title":"PD-1 blockade plus chemoradiotherapy as preoperative therapy for patients with BRPC\/LAPC: A biomolecular exploratory, phase II trial","volume":"4","author":"Du","year":"2023","journal-title":"Cell Rep Med"},{"key":"10.1016\/j.adro.2026.102128_bib0019","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-007586","article-title":"Multicenter randomized controlled trial of neoadjuvant chemoradiotherapy alone or in combination with pembrolizumab in patients with resectable or borderline resectable pancreatic adenocarcinoma","volume":"11","author":"Katz","year":"2023","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.adro.2026.102128_bib0020","doi-asserted-by":"crossref","first-page":"S1138","DOI":"10.1016\/j.annonc.2022.07.1431","article-title":"1299P PD-1 blockade plus chemotherapy followed by concurrent hypofractionated radiotherapy with simultaneous integrated boost as induction therapy for patients with borderline resectable and locally advanced pancreatic cancer: A phase II clinical trial","volume":"33","author":"Du","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.adro.2026.102128_bib0021","doi-asserted-by":"crossref","first-page":"3205","DOI":"10.1158\/1078-0432.CCR-24-3403","article-title":"A phase II study of neoadjuvant GVAX and cyclophosphamide combined with nivolumab and SBRT followed by surgery in borderline resectable pancreatic adenocarcinoma","volume":"31","author":"Agarwal","year":"2025","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.adro.2026.102128_bib0022","doi-asserted-by":"crossref","DOI":"10.1080\/07853890.2025.2541314","article-title":"Survival and pathological response in pancreatic ductal adenocarcinoma after preoperative therapy with PD-1 blockade plus chemoradiotherapy followed by surgical resection","volume":"57","author":"Abaydulla","year":"2025","journal-title":"Ann Med"},{"key":"10.1016\/j.adro.2026.102128_bib0023","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.adro.2018.07.005","article-title":"Exploring optimal sequencing of radiation and immunotherapy combinations","volume":"3","author":"Gunderson","year":"2018","journal-title":"Adv Radiat Oncol"},{"key":"10.1016\/j.adro.2026.102128_bib0024","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1002\/cncr.33424","article-title":"Immunotherapy and radiation therapy sequencing: State of the data on timing, efficacy, and safety","volume":"127","author":"Williamson","year":"2021","journal-title":"Cancer"},{"key":"10.1016\/j.adro.2026.102128_bib0025","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1148\/radiol.13131184","article-title":"Pancreatic ductal adenocarcinoma radiology reporting template: Consensus statement of the Society of Abdominal Radiology and the American Pancreatic Association","volume":"270","author":"Al-Hawary","year":"2014","journal-title":"Radiology"},{"key":"10.1016\/j.adro.2026.102128_bib0026","doi-asserted-by":"crossref","first-page":"4078","DOI":"10.1118\/1.3438081","article-title":"Stereotactic body radiation therapy: The report of AAPM Task Group 101","volume":"37","author":"Benedict","year":"2010","journal-title":"Med Phys"},{"key":"10.1016\/j.adro.2026.102128_bib0027","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1111\/j.1365-2559.2009.03376.x","article-title":"Classification of R1 resections for pancreatic cancer: The prognostic relevance of tumour involvement within 1 mm of a resection margin","volume":"55","author":"Campbell","year":"2009","journal-title":"Histopathology"},{"key":"10.1016\/j.adro.2026.102128_bib0028","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.pan.2019.01.001","article-title":"FOLFIRINOX for locally advanced pancreatic cancer: Results and prognostic factors of subset analysis from a nation-wide multicenter observational study in Japan","volume":"19","author":"Matsumoto","year":"2019","journal-title":"Pancreatology"},{"key":"10.1016\/j.adro.2026.102128_bib0029","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/S2468-1253(19)30327-9","article-title":"Nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer (LAPACT): A multicentre, open-label phase 2 study","volume":"5","author":"Philip","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.adro.2026.102128_bib0030","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1200\/JCO.21.02233","article-title":"Neoadjuvant chemoradiotherapy versus upfront surgery for resectable and borderline resectable pancreatic cancer: Long-term results of the Dutch randomized PREOPANC trial","volume":"40","author":"Versteijne","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.adro.2026.102128_bib0031","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S2468-1253(22)00348-X","article-title":"Immediate surgery compared with short-course neoadjuvant gemcitabine plus capecitabine, FOLFIRINOX, or chemoradiotherapy in patients with borderline resectable pancreatic cancer (ESPAC5): A four-arm, multicentre, randomised, phase 2 trial","volume":"8","author":"Ghaneh","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.adro.2026.102128_bib0032","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/S1470-2045(16)00172-8","article-title":"FOLFIRINOX for locally advanced pancreatic cancer: A systematic review and patient-level meta-analysis","volume":"17","author":"Suker","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.adro.2026.102128_bib0033","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1001\/jama.2016.4324","article-title":"Effect of chemoradiotherapy vs chemotherapy on survival in patients with locally advanced pancreatic cancer controlled after 4 months of gemcitabine with or without erlotinib: The LAP07 randomized clinical trial","volume":"315","author":"Hammel","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.adro.2026.102128_bib0034","doi-asserted-by":"crossref","first-page":"3266","DOI":"10.1200\/JCO-24-01502","article-title":"Benefit of chemoradiotherapy versus chemotherapy after induction therapy for conversion of unresectable into resectable pancreatic cancer: The randomized CONKO-007 trial","volume":"43","author":"Fietkau","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.adro.2026.102128_bib0035","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1016\/S1470-2045(25)00363-8","article-title":"Neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy in resectable and borderline resectable pancreatic cancer (PREOPANC-2): A multicentre, open-label, phase 3 randomised trial","volume":"26","author":"Janssen","year":"2025","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.adro.2026.102128_bib0036","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1200\/JCO.19.02274","article-title":"Preoperative chemoradiotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer: Results of the Dutch randomized phase III PREOPANC trial","volume":"38","author":"Versteijne","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.adro.2026.102128_bib0037","doi-asserted-by":"crossref","first-page":"4108","DOI":"10.1245\/s10434-025-17199-8","article-title":"Outcomes in locally advanced pancreatic cancer after induction ablative radiation therapy and resection","volume":"32","author":"Blair","year":"2025","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.adro.2026.102128_bib0038","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1001\/jamaoncol.2021.0057","article-title":"Association of ablative radiation therapy with survival among patients with inoperable pancreatic cancer","volume":"7","author":"Reyngold","year":"2021","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.adro.2026.102128_bib0039","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1038\/s41467-026-68976-2","article-title":"Neoadjuvant modified FOLFIRINOX plus nivolumab in borderline-resectable pancreatic ductal adenocarcinoma: A pilot phase 1 trial","volume":"17","author":"Wainberg","year":"2026","journal-title":"Nat Commun"},{"key":"10.1016\/j.adro.2026.102128_bib0040","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/S2468-1253(20)30330-7","article-title":"Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): A multicentre, randomised, phase 2 trial","volume":"6","author":"Kunzmann","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.adro.2026.102128_bib0041","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1001\/jamaoncol.2019.1588","article-title":"Durvalumab with or without tremelimumab for patients with metastatic pancreatic ductal adenocarcinoma: A phase 2 randomized clinical trial","volume":"5","author":"O'Reilly","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.adro.2026.102128_bib0042","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1200\/JCO.19.02931","article-title":"Randomized, multicenter, phase II trial of gemcitabine and cisplatin with or without veliparib in patients with pancreas adenocarcinoma and a germline BRCA\/PALB2 mutation","volume":"38","author":"O'Reilly","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.adro.2026.102128_bib0043","doi-asserted-by":"crossref","first-page":"e498","DOI":"10.1016\/S1470-2045(15)00007-8","article-title":"Radiation and checkpoint blockade immunotherapy: Radiosensitisation and potential mechanisms of synergy","volume":"16","author":"Sharabi","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.adro.2026.102128_bib0044","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41568-025-00903-x","article-title":"Radiation as an immune modulator: Mechanisms and implications for combination with immunotherapy","volume":"26","author":"Darragh","year":"2026","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.adro.2026.102128_bib0045","doi-asserted-by":"crossref","first-page":"eabg0117","DOI":"10.1126\/sciimmunol.abg0117","article-title":"Sequence of \u03b1PD-1 relative to local tumor irradiation determines the induction of abscopal antitumor immune responses","volume":"6","author":"Wei","year":"2021","journal-title":"Sci Immunol"},{"key":"10.1016\/j.adro.2026.102128_bib0046","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/S1470-2045(17)30380-7","article-title":"Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: A secondary analysis of the KEYNOTE-001 phase 1 trial","volume":"18","author":"Shaverdian","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.adro.2026.102128_bib0047","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1200\/JCO.21.01308","article-title":"Five-year survival outcomes from the PACIFIC trial: Durvalumab after chemoradiotherapy in stage III non\u2013small-cell lung cancer","volume":"40","author":"Spigel","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.adro.2026.102128_bib0048","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1056\/NEJMoa2032125","article-title":"Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer","volume":"384","author":"Kelly","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.adro.2026.102128_bib0049","article-title":"Stereotactic body radiotherapy for pancreatic cancer - A systematic review of prospective data","volume":"45","author":"Shouman","year":"2024","journal-title":"Clin Transl Radiat Oncol"},{"key":"10.1016\/j.adro.2026.102128_bib0050","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/j.ijrobp.2008.01.051","article-title":"Gemcitabine chemotherapy and single-fraction stereotactic body radiotherapy for locally advanced pancreatic cancer","volume":"72","author":"Schellenberg","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.adro.2026.102128_bib0051","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.radonc.2004.12.022","article-title":"Phase-II study on stereotactic radiotherapy of locally advanced pancreatic carcinoma","volume":"76","author":"Hoyer","year":"2005","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.adro.2026.102128_bib0052","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-002038","article-title":"Radiation dose and fraction in immunotherapy: One-size regimen does not fit all settings, so how does one choose?","volume":"9","author":"Demaria","year":"2021","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.adro.2026.102128_bib0053","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.ijrobp.2020.09.010","article-title":"A phase 1 dose escalation study of neoadjuvant SBRT plus elective nodal radiation with concurrent capecitabine for resectable pancreatic cancer","volume":"109","author":"Witt","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.adro.2026.102128_bib0054","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1001\/jamaoncol.2018.0329","article-title":"Total neoadjuvant therapy with FOLFIRINOX followed by individualized chemoradiotherapy for borderline resectable pancreatic adenocarcinoma: A phase 2 clinical trial","volume":"4","author":"Murphy","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.adro.2026.102128_bib0055","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1002\/cncr.32756","article-title":"Conventionally fractionated radiation therapy versus stereotactic body radiation therapy for locally advanced pancreatic cancer (CRiSP): An international systematic review and meta-analysis","volume":"126","author":"Tchelebi","year":"2020","journal-title":"Cancer"},{"key":"10.1016\/j.adro.2026.102128_bib0056","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1186\/s12885-017-3131-x","article-title":"A phase II study to evaluate LY2603618 in combination with gemcitabine in pancreatic cancer patients","volume":"17","author":"Laquente","year":"2017","journal-title":"BMC Cancer"},{"key":"10.1016\/j.adro.2026.102128_bib0057","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1001\/jamaoncol.2020.6564","article-title":"Efficacy of pazopanib with or without gemcitabine in patients with anthracycline- and\/or ifosfamide-refractory soft tissue sarcoma: Final results of the PAPAGEMO phase 2 randomized clinical trial","volume":"7","author":"Schmoll","year":"2021","journal-title":"JAMA Oncol"}],"container-title":["Advances in Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2452109426001351?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2452109426001351?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T11:35:13Z","timestamp":1792064113000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2452109426001351"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":57,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S2452109426001351"],"URL":"https:\/\/doi.org\/10.1016\/j.adro.2026.102128","relation":{},"ISSN":["2452-1094"],"issn-type":[{"value":"2452-1094","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Neoadjuvant Early Stereotactic Body Radiation Therapy Followed by Chemoimmunotherapy in Borderline Resectable and Locally Advanced Pancreatic Cancer","name":"articletitle","label":"Article Title"},{"value":"Advances in Radiation Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.adro.2026.102128","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of American Society for Radiation Oncology.","name":"copyright","label":"Copyright"}],"article-number":"102128"}}